This is a translation of a press release in Swedish 2019-01-29 Kancera AB (Nasdaq First North: KAN) today announces that the results of a study of lymphoma patients' immune cells show that the Fractalkine system is activated in the cancers of chronic...
Read MoreThis is a translation from the Swedish press release 2019-01-28 Kancera AB (Nasdaq First North: KAN) today announces that intermediate goals have been achieved prior to the planned start of clinical trials with the drug candidate KAND567 to demonstrate reduced tissue damage...
Read MoreThis is a translation of a pressrelease in Swedish from December 3rd 2018. Kancera AB announced today that the company has entered into an Research and Option agreement with Grünenthal, a leading pharmaceutical company in pain research and management. As part of...
Read MorePERIOD JAN – SEPTEMBER 2018, AND THIRD QUARTER IN BRIEF • Net sales for the period (January to September) amounted to SEK 0.1 million (SEK 0.1 million) of which the third quarter amounted to SEK 0.1 million (SEK 0.0 million). • R&D...
Read MoreHere follows a translation of a Swedish press release from November 23th 2018. Kancera announces that terms have been prepared for a shareholders' decision on investment in the company by Global Corporate Finance (GCF), New York. The investment, which covers a maximum...
Read MoreKancera AB today announced that the article entitled "Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination" has been published by researchers from Karolinska Institutet and Kancera AB in the journal Nature Communications1. The article documents the molecular mechanisms that give the small...
Read MoreKancera AB (publ) hereby reports on project activities and status for the preparation and implementation of a clinical study in cardiovascular inflammation associated with myocardial infarction. In the cancer area, it is announced that the research project funded by SWElife has been...
Read MorePERIOD 1 JAN – 30 JUNE 2018 IN BRIEF • Net sales for the period amounted to MSEK 0.0 (0.1 million). Sales for the second quarter were 0.0 MEK (0.1 M) • R & D expenses for the period amounted to SEK 20.8...
Read MoreThis is a translation of the Swedish press release published 2018-07-06. Kancera AB (publ) hereby announces that unique blockers (antagonists) of the Fractalkine system have been patented. Kancera intends to further develop a new drug candidate from the patented antagonists, and this...
Read MorePERIOD 1 JAN – 31 MARCH 2018 IN BRIEF • Net sales amounted to SEK 0 million (0 million) • R & D expenses amounted to SEK 11.8 million (8.3 M) • Operating profit amounted to SEK -12.5 million (-9.7 million) •...
Read More